Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension

European Journal of Human Genetics

Volumn 15, Issue 1, 2007, Pages 18-22

  Haberl, Ines ^a   Frei, Klemens ^b   Ramsebner, Reinhard ^b   Doberer, Daniel ^b   Petkov, Ventzislav ^b   Albinni, Sulaima ^b   Lang, Irene ^b   Lucas, Trevor ^b   Mosgoeller, Wilhelm ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; GENE SEQUENCE; GENETIC CODE; HEART RIGHT VENTRICLE FAILURE; HUMAN; IDIOPATHIC DISEASE; MALE; MUTATION; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN MODIFICATION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIGNAL TRANSDUCTION; WILD TYPE;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; EXONS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTRONS; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33845541206     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201711     Document Type: Article

References (15)

1. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
2. Petkov V, Mosgoeller W, Ziesche R et al: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346.
3. Said SI, Mutt V: Polypeptide with broaI biological activity: isolation from small intestine. Science 1970; 169: 1217-1218.
4. Gozes I, Bodner M, Shwartz H, Shani Y, Fridkin M: Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). Peptides 1984; 5: 161-166.
5. Yamagami T, Ohsawa K, Nishizawa M et al: Complete nucleotide sequence of human vasoactive intestinal peptide/PHM-27 gene and its inducible promoter. Ann NY Acad Sci 1988; 527: 87-102.
6. Rich S, Dantzker DR, Ayres SM et al: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
7. Sokal RR, Rohlf FJ: Biometry. W.H. Freeman and Company: New York, 1981.
8. Loscalzo J: Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001; 345: 367-371.
9. Newman JH, Trembath RC, Morse JA et al: Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 2004; 43: 33S-39S.
10. Liu D, Krajniak K, Chun D et al: VIP gene transcription is regulated by far upstream enhancer and repressor elements. Biochem Biophys Res Commun 2001; 284: 211-218.
11. Itoh N, Obata K, Yanaihara N, Okamoto H: Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 1983; 304: 547-549.
12. Barnes PJ: Neuropeptides iF human airways: function and clinical implications. Am Rev Respir Dis 1987; 136: S77-S83.
13. Schulte-Bockholt A, Meier DA, Hopp K et al: Gene expression and transcript size of the prepro-peptide VIP/PHM-27 in normal human tissue. Neurosci Lett 1993; 164: 101-104.
14. Asnicar MA, Koster A, Heiman ML et al: Vasoactive intestinal polypeptide/ pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 2002; 143: 3994-4006.
15. Otto C, Hein L, Brede M et al: Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 2004; 110: 3245-3251.